A5040354010- Inflammatory Bowel Disease
- Microscopic Colitis
- Helicobacter pylori-related gastroenterology studies
- Eosinophilic Esophagitis
- Diagnosis and treatment of tuberculosis
- Immunodeficiency and Autoimmune Disorders
- Autoimmune and Inflammatory Disorders
- Diverticular Disease and Complications
- Liver Diseases and Immunity
- Chronic Lymphocytic Leukemia Research
- Biosimilars and Bioanalytical Methods
- Anorectal Disease Treatments and Outcomes
- Liver Disease Diagnosis and Treatment
- Autoimmune and Inflammatory Disorders Research
- Health Systems, Economic Evaluations, Quality of Life
- Liver Disease and Transplantation
- Gastrointestinal Tumor Research and Treatment
- Celiac Disease Research and Management
- Gastrointestinal disorders and treatments
- Cell Adhesion Molecules Research
- Systemic Lupus Erythematosus Research
- Colorectal Cancer Treatments and Studies
- Pharmacological Effects of Natural Compounds
- IL-33, ST2, and ILC Pathways
- Immune Response and Inflammation
Hospital Clínic de Barcelona
2016-2025
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2016-2025
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2016-2025
Instituto de Salud Carlos III
2009-2025
Centro de Investigación Biomédica en Red
2012-2024
Central University Hospital of Asturias
2024
Hospital Universitari de Vic
2016-2024
Mayo Clinic in Arizona
2024
Western University
2024
University College London
2024
Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial. We further evaluated the of tofacitinib and maintenance therapy.
The strategy to reach the Consensus on guideline revisions involved six steps:1. Guideline statements of 2004 were analysed systematically by chairs working parties.Guideline selected for change and questions unresolved ECCO guidelines distributed party members.Participants asked answer based their experience as well evidence from literature (Delphi procedure). 62. In parallel, parties performed a systematic search topic with appropriate key words using Medline/Pubmed Cochrane database, own...
Ulcerative colitis is a chronic inflammatory disease of the colon for which current treatments are not universally effective. One additional treatment may be tofacitinib (CP-690,550), an oral inhibitor Janus kinases 1, 2, and 3 with in vitro functional specificity 1 over kinase expected to block signaling involving gamma chain-containing cytokines including interleukins 4, 7, 9, 15, 21. These integral lymphocyte activation, function, proliferation.In double-blind, placebo-controlled, phase 2...
Assessment of disease extension and activity is crucial to guide treatment in Crohn's disease. The objective the current cross-sectional study was determine accuracy MR for this assessment.50 patients with clinically active (n = 35) or inactive 15) underwent ileocolonoscopy (reference standard) MR. T2-weighted precontrast postcontrast-enhanced T1-weighted sequences were acquired. Endoscopic evaluated by CDEIS (Crohn's Disease Index Severity); addition endoscopic lesions classified as absent,...
The management of patients with IBD requires evaluation objective tools, both at the time diagnosis and throughout course disease, to determine location, extension, activity severity inflammatory lesions, as well as, potential existence complications. Whereas endoscopy is a well-established uniformly performed diagnostic examination, implementation radiologic techniques for assessment still heterogeneous; variations in technical aspects degrees experience preferences exist across countries...
Crohn's disease (CD) is a chronic progressive destructive disease. Currently available instruments measure activity at specific point in time. An instrument to cumulative structural damage the bowel, which may predict long-term disability, needed. The aim of this article outline methods develop an that can bowel damage. project being conducted by International Program New Indexes (IPNIC) group. This instrument, called Disease Digestive Damage Score (the Lémann score), should take into...
BackgroundThe use of magnetic resonance imaging (MRI) for assessment Crohn's disease (CD) is expanding. The aim this study to define and provide an external validation the MRI predictors active CD, severe a quantitative Magnetic Resonance Index Activity (MaRIA).
### 8.1 General Proctocolectomy with ileal pouch-anal anastomosis (IPAA) is the procedure of choice for most patients ulcerative colitis (UC) requiring colectomy.1 Pouchitis a non-specific inflammation reservoir and common complication IPAA in UC.2–7 Its frequency related to duration follow up, occurring up 50% 10 years after large series from major referral centres.1–9 The cumulative incidence pouchitis an familial adenomatous polyposis much lower, ranging 0 10%.10–12 Reasons higher UC...
Etrolizumab is a humanised monoclonal antibody that selectively binds the β7 subunit of heterodimeric integrins α4β7 and αEβ7. We aimed to assess etrolizumab in patients with moderately-to-severely active ulcerative colitis.In this double-blind, placebo-controlled, randomised, phase 2 study, colitis who had not responded conventional therapy were recruited from 40 referral centres 11 countries. Eligible (aged 18-75 years; Mayo Clinic Score [MCS] 5 higher [or ≥6 USA]; disease extending 25 cm...
<h3>Objective</h3> Tofacitinib is an oral, small-molecule Janus kinase inhibitor that being investigated for IBD. We evaluated the efficacy and safety of tofacitinib induction maintenance treatment in patients with moderate-to-severe Crohn9s disease (CD). <h3>Design</h3> conducted two randomised, double-blind, placebo-controlled, multicentre phase IIb studies. Adult CD were randomised to receive placebo, 5 or 10 mg twice daily 8 weeks. Those achieving clinical response-100 remission...